Search | Clinical Trials Finder

Conditions: Sepsis
Interventions: Blood Collection, Urine collection, Bioimpedance Analysis, Cognitive Function Tests, Quality-of-life Questionnaires, Physical Function Tests; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Lymphatic Disease, HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions: HspE7, placebo, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Orange, California

Conditions: Post-Treatment Lyme Disease
Interventions: taVNS; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Sepsis
Interventions: GFR by Iohexol, Urine Collection, Blood samples; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Post-Acute COVID-19 Syndrome
Interventions: Stem Cell; Biological
Lead sponsor: Charles Cox; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
Interventions: Inhaled nitric oxide, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 14 Days
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1998
U.S. locations: 11
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more

Conditions: HIV, Coronary Artery Disease
Interventions: metformin extended release; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Persistent Fetal Circulation Syndrome, Diaphragmatic Hernia, Meconium Aspiration, Sepsis
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 30 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: AL 721; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • New Orleans, Louisiana • Minneapolis, Minnesota + 2 more

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Persistent Infection, Cystic Fibrosis
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more

Conditions: HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
Interventions: FT538, Vorinostat; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions: Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test; Procedure · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Cytomegalovirus
Interventions: CMV-pp65 CTLs; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: HPV Infection, HIV Infections, HPV-Related Malignancy
Interventions: Mail-based Saliva Sample Kit, Study-related Surveys; Diagnostic Test · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: NmVac4-A/C/Y/W-135-DT™; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Chronic Rhinitis
Interventions: Oxymetazoline Hydrochloride; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Conditions: MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions: Exebacase; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Butte, Montana • Toledo, Ohio

Conditions: HIV Infections
Interventions: Concentration-controlled therapy; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

PICS: Subtitle Cardiac Dysfunction in Older Sepsis Survivors

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

taVNS for Persistent Symptoms From Lyme Disease

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

Stem Cell Study for Long COVID-19 Neurological Symptoms

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

Metformin for HIV Inflammation

Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO

A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Alternative Dosing Strategy for Anti-HIV Drugs